Kardiologie Hassloch

Research site

Germany Hans Boeckler Strasse 25, 67454 Hassloch, Germany

2 trials recruiting
Cardiovascular disorder · Type 2 diabetes mellitus · Hypertension
Adult patients

About Specializations

Kardiologie Hassloch in Hassloch, Germany specialises in clinical trials of conditions such as Cardiovascular disorder, Type 2 diabetes mellitus, Hypertension, Arteriosclerosis, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

Kardiologie Hassloch focuses its clinical research on cardiovascular diseases, aiming to evaluate new therapies that lower major adverse cardiovascular events and improve heart function in patients with diverse risk profiles.

Atherosclerotic cardiovascular disease
Heart failure with preserved or mildly reduced ejection fraction and systemic inflammation
Type 2 diabetes with cardiovascular involvement
Hypertension
Combined risk of diabetes, hypertension and established cardiovascular disease

Recent studies at the site test agents such as AZD0780, the vicadrostat‑empagliflozin combination, and ziltivekimab, seeking to demonstrate superiority over placebo in preventing cardiovascular death, heart‑failure hospitalizations, and major vascular events.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Hans Boeckler Strasse 2567454 HasslochGermany

Open in maps ↗

Recruiting now: 2 trials
Conditions studied: 5

More sites in Hassloch Germany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

3 clinical trials

Cardiovascular disorder+2

Recruiting

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:BI 690517
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Germany

Participants:18–64 years · 65+ years
Sponsor:AstraZeneca AB

Contact Research Centre

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Ziltivekimab
Sponsor:Novo Nordisk A/S

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites